← Back to Search

Alpha V Beta 6 Integrin Inhibitor

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ (IPF-201 Trial)

Phase 2
Waitlist Available
Research Sponsored by Pliant Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up following 1 day of administration of pln-74809
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a special imaging agent to help doctors see how well a specific lung protein is affected in patients with mild to moderate IPF.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~following 1 day of administration of pln-74809
This trial's timeline: 3 weeks for screening, Varies for treatment, and following 1 day of administration of pln-74809 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With a Predicted Effect on αVβ6 PET ( Positron Emission Tomography) in Lungs After Administration of Drug.
Secondary study objectives
Safety and Tolerability of PLN-74809 as Measured by the Number / Percentage of Adverse Events
Other study objectives
Relationship between PLN-74809 systemic exposure, αvβ6 receptor occupancy and biomarkers in IPF participants

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Group I: PLN-74809 Dose Level 4 (320 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 4 (320 mg)
Group II: PLN-74809 Dose Level 4 (240 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 4 (240 mg)
Group III: PLN-74809 Dose Level 3 (120 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 3 (120 mg)
Group IV: PLN-74809 Dose Level 2 (80 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 2 (80 mg)
Group V: PLN-74809 Dose Level 1 (60 mg)Experimental Treatment2 Interventions
PLN-74809 Dose Level 1 (60mg)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PLN-74809
2020
Completed Phase 2
~260
Knottin tracer
2020
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Stanford UniversityOTHER
2,484 Previous Clinical Trials
17,516,112 Total Patients Enrolled
4 Trials studying Idiopathic Pulmonary Fibrosis
90 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
724 Total Patients Enrolled
4 Trials studying Idiopathic Pulmonary Fibrosis
520 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Pliant Therapeutics Medical MonitorStudy DirectorPliant Therapeutics, Inc.
4 Previous Clinical Trials
678 Total Patients Enrolled
2 Trials studying Idiopathic Pulmonary Fibrosis
480 Patients Enrolled for Idiopathic Pulmonary Fibrosis
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top